The Myeloproliferative Disorders Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Myeloproliferative Disorders Drugs Market:
https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report
According to The Business Research Company’s Myeloproliferative Disorders Drugs Global Market Report 2024, The myeloproliferative disorders drugs market size has grown strongly in recent years. It will grow from $9.11 billion in 2023 to $9.58 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increased incidence of myeloproliferative disorders, advancements in understanding disease mechanisms, clinical research and drug development, improvements in diagnosis and screening, patient advocacy and awareness.
The myeloproliferative disorders drugs market size is expected to see steady growth in the next few years. It will grow to $11.15 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to aging population, advancements in precision medicine, emergence of novel therapies, global focus on rare diseases, government initiatives and healthcare policies. Major trends in the forecast period include precision medicine approaches, clinical trials for investigational therapies, improved symptom management, expanded use of ruxolitinib, focus on disease biomarkers.
The rise in the incidence of myeloproliferative disorders is expected to propel the growth of the myeloproliferative disorder’s drugs market going forward. Myeloproliferative disorders refer to a diverse category of diseases distinguished from acute leukemia by the cellular growth of one or more hematologic cell lines in the peripheral blood. The rise in myeloproliferative disorders is mostly driven by genetic disorders, overexposure to radiation, electrical wiring, or chemicals, the geriatric population. Myeloproliferative disease drugs block the BCR-ABL protein by binding to the ATP pocket in the active site, inhibiting downstream phosphorylation of the target protein, which helps in the treatment of the myeloproliferative disorder. For instance, in August 2022, according to the National Institute of Health, a US-based medical research agency, in 2022, chronic myelogenous leukemia was more common in men, with an incidence rate of roughly 2.4 new cases per 100,000 compared to 1.4 new cases per 100,000 in women, compared to 1.7 new cases per 100,000 men and women per year in 2020. Therefore, the rise in the incidence of myeloproliferative disorders is driving the growth of the myeloproliferative disorders drug market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10681&type=smp
The myeloproliferative disorders drugs market covered in this report is segmented –
1) By Type: Primary Myelofibrosis, Polycythemia Vera (PV), Essential Thrombocythemia (ET), Chronic Eosinophilic Leukemia Or Hyper eosinophilic Syndrome (HES), Systemic Masto cytosis (SM)
2) By Drug Type: JAK2 Inhibitors, Anti-Neoplastics, Demethylation Agents, Imatinib Mesylate, Other Drug Types
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Stores, Drug Stores
Product innovation has emerged as a key trend gaining popularity in the myeloproliferative disorder drugs market. Major companies operating in myeloproliferative disorder market are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in September 2023, GSK plc, a UK-based pharmaceutical and biotechnology company, announced the FDA approval for momelotinib for the treatment of primary myelofibrosis, a type of myeloproliferative disorder (MPD). It is a potentially novel medication with a distinct mode of action that includes the capacity to block three important signaling pathways: activin A receptor type I (ACVR1), Janus kinase (JAK) 1, and JAK2. JAK1 and JAK2 inhibition may alleviate splenomegaly and constitutional symptoms. Furthermore, circulating hepcidin, which is increased in myelofibrosis and contributes to anemia, decreases as a result of direct inhibition of ACVR1.
The myeloproliferative disorders drugs market report table of contents includes:
1. Executive Summary
2. Myeloproliferative Disorders Drugs Market Characteristics
3. Myeloproliferative Disorders Drugs Market Trends And Strategies
4. Myeloproliferative Disorders Drugs Market – Macro Economic Scenario
5. Global Myeloproliferative Disorders Drugs Market Size and Growth
………………
31. Global Myeloproliferative Disorders Drugs Market Competitive Benchmarking
32. Global Myeloproliferative Disorders Drugs Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Myeloproliferative Disorders Drugs Market
34. Myeloproliferative Disorders Drugs Market Future Outlook and Potential Analysis
35. Appendix
Read Related Topics:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
